Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study is evaluating a combination of drugs called sirolimus and vandetanib to treat
glioblastoma. Sirolimus has been approved for use in patients who undergo organ transplants.
Sirolimus works by suppressing the immune system so the body will not reject the transplanted
organ. Vandetanib is an investigational drug and we are trying to find the highest and safest
dose of vandetanib with sirolimus that can be given safely.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
AstraZeneca Brigham and Women's Hospital Dana-Farber Cancer Institute